SCHEMBL4415920

SCHEMBL4415920

CC(C)OC(=O)N1CCC(OCc2noc(-c3ccc(S(C)(=O)=O)cc3)n2)CC1

nearest known ligand 0.54

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.54
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4423386 0.87 GPR119 (0.43) GPR119
SCHEMBL4552048 0.87 GPR119 (0.54) GPR119
SCHEMBL4421909 0.86 GPR119 (0.44) GPR119
SCHEMBL4419176 0.86 GPR119 (0.43) GPR119
SCHEMBL4422114 0.86 GPR119 (0.46) GPR119CYP2C9
SCHEMBL13598260 0.85 GPR119 (0.39) GPR119
SCHEMBL4562543 0.84 GPR119 (0.43) GPR119CYP2C9
SCHEMBL4424816 0.84 GPR119 (0.58) GPR119
SCHEMBL610267 0.83 CPT2 (0.41) GPR119
SCHEMBL10058389 0.81 GPR119 (0.39) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885CYP2C9 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.